No data to show
OTCM
DVHGF
Market cap17mUSD
Sep 15, Last price
0.18USD
IPO
-55.88%
Name
Devonian Health Group Inc
Chart & Performance
P/E
—
P/S
2.01
EPS
—
Div Yield, %
—
Shrs. gr., 5y
16.88%
Rev. gr., 5y
24.58%
Revenues
18m
+659.60%
Net income
-1m
L-73.38%
CFO
6m
P
Profile
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, a Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric or duodenal ulcers; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, it acquires drug and health product licenses; and distributes pharmaceutical products. Devonian Health Group Inc. has a strategic alliance with CannTx Life Sciences Inc. for the development of cannabinoid-based pharmaceutical drugs. The company was incorporated in 2015 and is headquartered in Québec, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑07 | 2023‑07 | 2022‑07 | 2021‑07 | 2020‑07 | 2019‑07 | 2018‑07 | 2017‑07 | 2016‑07 | |
| Income | |||||||||
Revenues | 17,816 659.60% | 2,345 1.74% | |||||||
Cost of revenue | 18,674 | 6,745 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (858) | (4,399) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | (858) | (4,399) | |||||||
Net income | (1,225) -73.38% | (4,600) 33.39% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 708 | 1,163 | |||||||
BB yield | -2.60% | ||||||||
| Debt | |||||||||
Debt current | 2,120 | 3,602 | |||||||
Long-term debt | 296 | 167 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (7,446) | (1,294) | |||||||
| Cash flow | |||||||||
Cash from operating activities | 5,634 | (4,356) | |||||||
CAPEX | (4) | ||||||||
Cash from investing activities | (4) | 5,000 | |||||||
Cash from financing activities | (830) | 1,614 | |||||||
FCF | (644) | (4,225) | |||||||
| Balance | |||||||||
Cash | 9,863 | 5,063 | |||||||
Long term investments | |||||||||
Excess cash | 8,972 | 4,946 | |||||||
Stockholders' equity | 3,187 | 10,483 | |||||||
Invested Capital | 13,521 | 12,976 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 147,110 | 135,566 | |||||||
Price | 0.19 | ||||||||
Market cap | 27,215 | ||||||||
EV | 19,769 | ||||||||
EBITDA | (186) | (3,976) | |||||||
EV/EBITDA | |||||||||
Interest | 380 | 460 | |||||||
Interest/NOPBT | |||||||||